<SEC-DOCUMENT>0001193125-20-109597.txt : 20200417
<SEC-HEADER>0001193125-20-109597.hdr.sgml : 20200417
<ACCEPTANCE-DATETIME>20200416205002
ACCESSION NUMBER:		0001193125-20-109597
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200416
FILED AS OF DATE:		20200417
DATE AS OF CHANGE:		20200416

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		20797530

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d852660d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated April 16, 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by
furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Immutep Advances Cell Line Development for IMP761</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: April 16, 2020 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U></U>Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d852660dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level 12, 95 Pitt Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g852660g26u16.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX/Media Announcement </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Advances Cell
Line Development for IMP761 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; April</B><B></B><B>&nbsp;16, 2020 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP)
(&#147;Immutep&#148; or &#147;the Company&#148;), is pleased to announce that Batavia Biosciences, its manufacturing partner for its preclinical candidate, IMP761, has made significant progress in the cell line development for the product candidate
which is an immunosuppressive agonist antibody to <FONT STYLE="white-space:nowrap">LAG-3.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using its STEP<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>-mAb technology, Batavia Biosciences has developed a pharmaceutical-grade, stable CHO cell line that produces significantly high product yields of IMP761. The Company will now complete the
preparations for the Good Manufacturing Practice (GMP) process compliance development phase, ahead of clinical testing of the compound in autoimmune disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep reported encouraging preclinical results from its studies of IMP761 in early 2019. The <I>in vivo</I> studies showed that IMP761 decreases
inflammatory T cell infiltration induced by intra-dermal injection of an antigen. As a targeted immunosuppressive antibody, IMP761 has the potential to address the root cause of autoimmune diseases by specifically silencing the autoimmune memory T
cells accumulating at the disease site which express <FONT STYLE="white-space:nowrap">LAG-3</FONT> as an exhaustion marker after being repeatedly stimulated with dominant self-peptides at the disease site. These findings were published in the
<U>peer-reviewed paper</U> in the <I>Journal of Immunology, </I>in January 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Batavia Biosciences&#146; CEO, Menzo Havenga Ph.D., said:</B>
&#147;We are pleased that our STEP<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>-mAb proves its value in the development of this important IgG4-based <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy product, IMP761.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immutep CEO, Marc Voigt stated:</B> &#147;IMP761 is the first agonist antibody that targets the immune checkpoint
<FONT STYLE="white-space:nowrap">LAG-3</FONT> for the treatment of autoimmune diseases, such as inflammatory bowel diseases, rheumatoid arthritis, and multiple sclerosis. The cell line which was developed seems to be highly potent and we are excited
to be moving closer to clinical testing of this promising product candidate to treat the root cause of autoimmune diseases.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology company that is a leader in the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related
immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g852660g26u16.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;),
a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein <FONT STYLE="white-space:nowrap">(LAG-3Ig)</FONT> based on the <FONT STYLE="white-space:nowrap">LAG-3</FONT> immune control mechanism. This mechanism plays a vital role in the
regulation of the T cell immune response. Efti is currently in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT02614833); a Phase II clinical trial being conducted in
collaboration with Merck&nbsp;&amp; Co., Inc., Kenilworth, NJ, USA (known as &#147;MSD&#148; outside the United States and Canada) referred to as <FONT STYLE="white-space:nowrap">TACTI-002</FONT> to evaluate a combination of efti with KEYTRUDA<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier NCT03625323); a Phase I clinical trial being conducted in collaboration with Merck KGaA, Darmstadt, Germany and
Pfizer Inc. referred to as <FONT STYLE="white-space:nowrap">INSIGHT-004</FONT> to evaluate a combination of efti with avelumab (clinicaltrials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed
TACTI-mel (clinicaltrials.gov identifier NCT02676869). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products, including antibodies, for
immune response modulation in autoimmunity and cancer are being developed by Immutep&#146;s large pharmaceutical partners. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Garth Russell, LifeSci Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646) <FONT STYLE="white-space:nowrap">876-3613;</FONT> <U>garth@lifesciadvisors.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the board of Immutep Limited. </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level 12, 95 Pitt Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g852660g26u16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g852660g26u16.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * $9@JEF( '))[4!L<O?>-K:"4QVD
M!N .-Y;:I^GK63JI;')/%13M%7'6'C*&>;RKNU>WQU<?,J_7CBA5$]PAB4W:
M2L=,"&4%2"#R"*U.L6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MFC[;E4EY,]VTZ[%]IMM=#_EK&K?0D<U]K1J*I3C-=4?#UJ;I5)0?1EJM3(*
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M=^>,9]/K0!WOA/Q5=^(+RXAN;2.%8D# KGGG'>@"[XD\56OAZ-4*>==2#*1
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M$CE)8E5A^E %[2[GP[?WKIID=J\T #%HX0-O;@X_E0!P'Q#_ .1J;_K@G]:
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MT/-S3#*A6O':6ITM>H>4% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MJ<=D?)5ZTJ]1U);LM5L8A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M["X2GA8VCOU9X&+QE3%2O+;HC3KL.,* "@ H * "@ H * "@ H * "@ H *
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MSVVW=BTQ!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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)[%%D'+'L?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
